Oxymatrine Alleviates High-Fat-High-Fructose-Induced Fatty Liver in Rats: Understanding the Molecular Mechanism Through an Untargeted Metabonomics Study

References

• Pan J, Zhou W, Xu R, Xing L, Ji G, Dang Y. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease. Biomed Pharmacother. 2022;151:113127. doi: 10.1016/j.biopha.2022.113127
   PubMed Web of Science ®Google Scholar
• Alwahsh SM, Gebhardt R. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol. 2017;91(4):1545–1563. doi: 10.1007/s00204-016-1892-7
   PubMed Web of Science ®Google Scholar
• Longato L. Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair. 2013;6(1):14. doi: 10.1186/1755-1536-6-14
   PubMedGoogle Scholar
• Kamboj P, Sarkar S, Gupta SK, Bisht N, Kumari D, Alam MJ. Methanolic extract of Lysimachia Candida Lindl. Prevents high-fat high-fructose-induced fatty liver in rats: understanding the molecular mechanism through untargeted metabolomics study. Front Pharmacol. 2021;12:653872. doi: 10.3389/fphar.2021.653872
   PubMed Web of Science ®Google Scholar
• Jensen VS, Hvid H, Damgaard J, Nygaard H, Ingvorsen C, Wulff EM. Dietary fat stimulates development of NAFLD more potently than dietary fructose in Sprague-Dawley rats. Diabetol Metab Syndr. 2018;10:4. doi: 10.1186/s13098-018-0307-8
   PubMed Web of Science ®Google Scholar
• Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321–350. doi: 10.1146/annurev-pathol-020117-043617
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi: 10.1016/j.metabol.2015.12.012
   PubMed Web of Science ®Google Scholar
• Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab. 2021;50:101122.
   PubMed Web of Science ®Google Scholar
• Hua S, Gu M, Wang Y, Ban D, Ji H. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells. Clin Transl Oncol. 2021;23(4):750–756. doi: 10.1007/s12094-020-02464-x
   PubMed Web of Science ®Google Scholar
• Zhu YX, Hu HQ, Zuo ML, Mao L, Song GL, Li TM. Effect of oxymatrine on liver gluconeogenesis is associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation. Biomed Rep. 2021;15(1):56. doi: 10.3892/br.2021.1432
   PubMed Web of Science ®Google Scholar
• Huan DQ, Hop NQ, Son NT. Oxymatrine: a current overview of its health benefits. Fitoterapia. 2023;168:105565. doi: 10.1016/j.fitote.2023.105565
   PubMed Web of Science ®Google Scholar
• Shi LJ, Shi L, Song GY, Zhang HF, Hu ZJ, Wang C. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparalpha). Eur J Pharmacol. 2013;714(1–3):89–95. doi: 10.1016/j.ejphar.2013.06.013
   PubMed Web of Science ®Google Scholar
• Son JW, Shoaie S, Lee S. Systems biology: a multi-omics integration approach to metabolism and the microbiome. Endocrinol Metab (Seoul). 2020;35(3):507–514. doi: 10.3803/EnM.2020.303
   PubMedGoogle Scholar
• Xie Z, Li H, Wang K, Lin J, Wang Q, Zhao G. Analysis of transcriptome and metabolome profiles alterations in fatty liver induced by high-fat diet in rat. Metabolism. 2010;59(4):554–560. doi: 10.1016/j.metabol.2009.08.022
   PubMed Web of Science ®Google Scholar
• Hansen M, Baunsgaard D, Autrup H, Vogel UB, Moller P, Lindecrona R. Sucrose, glucose and fructose have similar genotoxicity in the rat colon and affect the metabolome. Food Chem Toxicol. 2008;46(2):752–760. doi: 10.1016/j.fct.2007.09.110
   PubMed Web of Science ®Google Scholar
• Abd ES, El-Den AE. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol. 2015;7(6):846–858. doi: 10.4254/wjh.v7.i6.846
   PubMedGoogle Scholar
• Wang Y, Wu J, Shi A. Literature review on the use of herbal extracts in the treatment of non- alcoholic fatty liver disease. Endocr Metab Immune Disord Drug Targets. 2022;22(11):1123–1145. doi: 10.2174/1871530322666220408123746
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang L, Wang Y, Huang W, Li Y, Chen S. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease. Life Sci. 2020;257:118090. doi: 10.1016/j.lfs.2020.118090
   PubMed Web of Science ®Google Scholar
• Muller C, Hank E, Giera M, Bracher F. Dehydrocholesterol reductase 24 (DHCR24): medicinal chemistry, pharmacology and novel therapeutic options. Curr Med Chem. 2022;29(23):4005–4025. doi:10.2174/0929867328666211115121832
   PubMed Web of Science ®Google Scholar
• Simonen M, Mannisto V, Leppanen J, Kaminska D, Karja V, Venesmaa S. Desmosterol in human nonalcoholic steatohepatitis. Hepatology. 2013;58(3):976–982. doi: 10.1002/hep.26342
   PubMed Web of Science ®Google Scholar
• Hirotani Y, Ozaki N, Tsuji Y, Urashima Y, Myotoku M. Effects of eicosapentaenoic acid on hepatic dyslipidemia and oxidative stress in high fat diet-induced steatosis. Int J Food Sci Nutr. 2015;66(5):569–573. doi: 10.3109/09637486.2015.1042848
   PubMed Web of Science ®Google Scholar
• Bhat SF, Pinney SE, Kennedy KM, McCourt CR, Mundy MA, Surette MG. Exposure to high fructose corn syrup during adolescence in the mouse alters hepatic metabolism and the microbiome in a sex-specific manner. J Physiol. 2021;599(5):1487–1511. doi: 10.1113/JP280034
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids. 2015;47(3):603–615. doi: 10.1007/s00726-014-1894-9
   PubMed Web of Science ®Google Scholar
• Demirel M, Koktasoglu F, Ozkan E, Dulun AH, Gul AZ, Sharifov R. Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2023;58(11):1344–1350. doi: 10.1080/00365521.2023.2225667
   PubMed Web of Science ®Google Scholar
• Amanatidou AI, Mikropoulou EV, Amerikanou C, Milanovic M, Stojanoski S, Bjelan M. Plasma amino acids in NAFLD patients with obesity are associated with steatosis and fibrosis: results from the MAST4HEALTH study. Metabolites. 2023;13:8. doi:10.3390/metabo13080959
   Web of Science ®Google Scholar
• Gagnon E, Manikpurage HD, Mitchell PL, Girard A, Gobeil E, Bourgault J. Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease. iScience. 2023;26(7):107127. doi: 10.1016/j.isci.2023.107127
   PubMed Web of Science ®Google Scholar
• Zhang D, Zheng W, Li X, Liang G, Ye N, Liu Y. Investigation of obesity-alleviation effect of eurycoma longifolia on mice fed with a high-fat diet through metabolomics revealed enhanced decomposition and inhibition of accumulation of lipids. J Proteome Res. 2021;20(5):2714–2724. doi: 10.1021/acs.jproteome.1c00015
   PubMed Web of Science ®Google Scholar
• Sonnweber T, Pizzini A, Nairz M, Weiss G, Tancevski I. Arachidonic acid metabolites in cardiovascular and metabolic diseases. Int J Mol Sci. 2018;19(11):3285. doi: 10.3390/ijms19113285
   PubMed Web of Science ®Google Scholar
• Wang L, Zhi Y, Ye Y, Zhang M, Mai Z, Xia W. Metabolomic analysis identifies the regulation of lipid metabolism pathway as potential mechanisms of Jiangzhi decoction against non-alcoholic fatty liver disease. J Pharm Pharmacol. 2023;75(10):1366–1377. doi: 10.1093/jpp/rgad067
   PubMed Web of Science ®Google Scholar
• Sztolsztener K, Chabowski A, Harasim-Symbor E, Bielawiec P, Konstantynowicz-Nowicka K. Arachidonic acid as an early indicator of inflammation during non-alcoholic fatty liver disease development. Biomolecules. 2020;10:8. doi: 10.3390/biom10081133
   Web of Science ®Google Scholar
• Chashmniam S, Mirhafez SR, Dehabeh M, Hariri M, Azimi NM, Nobakht MGB. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr. 2019;73(9):1224–1235. doi: 10.1038/s41430-018-0386-5
   PubMed Web of Science ®Google Scholar
• Muyyarikkandy MS, McLeod M, Maguire M, Mahar R, Kattapuram N, Zhang C. Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during NAFLD. FASEB J. 2020;34(11):14832–14849. doi: 10.1096/fj.202001495R
   PubMed Web of Science ®Google Scholar
• Papadopoulos G, Legaki AI, Georgila K, Vorkas P, Giannousi E, Stamatakis G. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity. Metabolism. 2023;144:155552. doi: 10.1016/j.metabol.2023.155552
   PubMed Web of Science ®Google Scholar
• Sun R, Xu D, Wei Q, Zhang B, Aa J, Wang G. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020;123:109721. doi: 10.1016/j.biopha.2019.109721
   PubMed Web of Science ®Google Scholar
• Fotakis C, Kalafati IP, Amanatidou AI, Andreou V, Matzapetakis M, Kafyra M. Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD. Front Endocrinol (Lausanne). 2023;14:1230457. doi: 10.3389/fendo.2023.1230457
   PubMed Web of Science ®Google Scholar
• Yang JH, Byeon EH, Kang D, Hong SG, Yang J, Kim DR. Fermented soybean paste attenuates biogenic amine-induced liver damage in obese mice. Cells. 2023;12:5. doi: 10.3390/cells12050822
   Web of Science ®Google Scholar
• Yamada S, Tanimoto A, Sasaguri Y. Critical in vivo roles of histamine and histamine receptor signaling in animal models of metabolic syndrome. Pathol Int. 2016;66(12):661–671. doi: 10.1111/pin.12477
   PubMed Web of Science ®Google Scholar
• Yamada S, Guo X, Wang KY, Tanimoto A, Sasaguri Y. Novel function of histamine signaling via histamine receptors in cholesterol and bile acid metabolism: histamine H2 receptor protects against nonalcoholic fatty liver disease. Pathol Int. 2016;66(7):376–385. doi: 10.1111/pin.12423
   PubMed Web of Science ®Google Scholar
• Toledo-Ibelles P, Gutierrez-Vidal R, Calixto-Tlacomulco S, Delgado-Coello B, Mas-Oliva J. Hepatic accumulation of hypoxanthine: a link between hyperuricemia and nonalcoholic fatty liver disease. Arch Med Res. 2021;52(7):692–702. doi: 10.1016/j.arcmed.2021.04.005
   PubMed Web of Science ®Google Scholar
• Hegazy M, Elsayed NM, Ali HM, Hassan HG, Rashed L. Diabetes mellitus, nonalcoholic fatty liver disease, and conjugated linoleic acid (Omega 6): what is the link? J Diabetes Res. 2019;2019:5267025. doi: 10.1155/2019/5267025
   PubMedGoogle Scholar
• Pertiwi K, Kupers LK, Geleijnse JM, Zock PL, Wanders AJ, Kruger HS. Associations of linoleic acid with markers of glucose metabolism and liver function in South African adults. Lipids Health Dis. 2020;19(1):138. doi: 10.1186/s12944-020-01318-3
   PubMed Web of Science ®Google Scholar
• Naughton SS, Mathai ML, Hryciw DH, McAinch AJ. Linoleic acid and the pathogenesis of obesity. Prostaglandins Other Lipid Mediat. 2016;125:90–99. doi: 10.1016/j.prostaglandins.2016.06.003
   PubMed Web of Science ®Google Scholar
• Marangoni F, Agostoni C, Borghi C, Catapano AL, Cena H, Ghiselli A. Dietary linoleic acid and human health: focus on cardiovascular and cardiometabolic effects. Atherosclerosis. 2020;292:90–98. doi: 10.1016/j.atherosclerosis.2019.11.018
   PubMed Web of Science ®Google Scholar
• Chen H, Tan H, Wan J, Zeng Y, Wang J, Wang H. PPAR-gamma signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets. Pharmacol Ther. 2023;245:108391. doi: 10.1016/j.pharmthera.2023.108391
   PubMed Web of Science ®Google Scholar